TABLE III.
Summary of Adverse Events
| N = 22, n (%) | 3,292 patient-weeks, n (ratea) | |
|---|---|---|
| Patients reporting any adverse events (AE) | 22 (100) | 745 (22.63) |
| Patients reporting any severe AE | 9 (40.9) | 20 (0.61) |
| Patients reporting any serious AE | 7 (31.8) | 14 (0.43) |
| Patients reporting any treatment-related AE | 6 (27.3) | 37 (1.12) |
| Patients reporting any serious treatment-related AE | 0 (0) | 0 (0) |
| Fatal AE | 0 (0) | 0 (0) |
| Patients who withdrew from study or romiplostim due to AE | 0 (0) | 0 (0) |
| AEs of interest | ||
| Bone marrow fibrosis | 0 (0) | 0 (0) |
| Thrombotic events | 0 (0) | 0 (0) |
| Antibodies to romiplostim or TPO | 0 (0) | 0 (0) |
a
Rate is exposure-adjusted incidence for 100 patient-weeks.